CHARLES RIVER LABORATORIES (CRL)
US1598641074 - Common Stock
Taking everything into account, CRL scores 5 out of 10 in our fundamental rating. CRL was compared to 55 industry peers in the Life Sciences Tools & Services industry. CRL scores excellent on profitability, but there are concerns on its financial health. CRL has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
CRL had positive earnings in the past year.
In the past year CRL had a positive cash flow from operations.
CRL had positive earnings in each of the past 5 years.
In the past 5 years CRL always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of CRL (5.16%) is better than 83.64% of its industry peers.
With an excellent Return On Equity value of 10.92%, CRL belongs to the best of the industry, outperforming 83.64% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 7.07%, CRL belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
CRL had an Average Return On Invested Capital over the past 3 years of 8.07%. This is below the industry average of 10.44%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.16% | ||
| ROE | 10.92% | ||
| ROIC | 7.07% |
ROA(3y)5.92%
ROA(5y)5.95%
ROE(3y)14.99%
ROE(5y)15.52%
ROIC(3y)8.07%
ROIC(5y)7.97%
1.3 Margins
CRL's Profit Margin of 10.17% is amongst the best of the industry. CRL outperforms 83.64% of its industry peers.
In the last couple of years the Profit Margin of CRL has grown nicely.
The Operating Margin of CRL (15.04%) is better than 80.00% of its industry peers.
CRL's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 35.93%, CRL is doing worse than 60.00% of the companies in the same industry.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.04% | ||
| PM (TTM) | 10.17% | ||
| GM | 35.93% |
OM growth 3Y0.93%
OM growth 5Y0.35%
PM growth 3Y-2.65%
PM growth 5Y2.84%
GM growth 3Y0.29%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, CRL has more shares outstanding
The number of shares outstanding for CRL has been increased compared to 5 years ago.
CRL has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.63 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
CRL has a Altman-Z score of 2.63. This is comparable to the rest of the industry: CRL outperforms 52.73% of its industry peers.
CRL has a debt to FCF ratio of 4.16. This is a neutral value as CRL would need 4.16 years to pay back of all of its debts.
CRL has a better Debt to FCF ratio (4.16) than 76.36% of its industry peers.
A Debt/Equity ratio of 0.62 indicates that CRL is somewhat dependend on debt financing.
CRL's Debt to Equity ratio of 0.62 is on the low side compared to the rest of the industry. CRL is outperformed by 67.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | 4.16 | ||
| Altman-Z | 2.63 |
ROIC/WACC0.65
WACC10.91%
2.3 Liquidity
CRL has a Current Ratio of 1.48. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CRL (1.48) is worse than 76.36% of its industry peers.
CRL has a Quick Ratio of 1.14. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.14, CRL is doing worse than 72.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.48 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.40%.
CRL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.09% yearly.
The Revenue has decreased by -3.67% in the past year.
CRL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.75% yearly.
EPS 1Y (TTM)-9.4%
EPS 3Y9.37%
EPS 5Y12.09%
EPS Q2Q%-4.78%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y12.2%
Revenue growth 5Y12.75%
Sales Q2Q%-1.64%
3.2 Future
Based on estimates for the next years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.52% on average per year.
Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 5.66% on average per year.
EPS Next Y-3.64%
EPS Next 2Y-1.17%
EPS Next 3Y2.89%
EPS Next 5Y9.52%
Revenue Next Year-1.95%
Revenue Next 2Y-0.39%
Revenue Next 3Y1.75%
Revenue Next 5Y5.66%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.34, which indicates a rather expensive current valuation of CRL.
Based on the Price/Earnings ratio, CRL is valued cheaper than 92.73% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.29, CRL is valued a bit cheaper.
A Price/Forward Earnings ratio of 18.82 indicates a rather expensive valuation of CRL.
CRL's Price/Forward Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 85.45% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.01. CRL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.34 | ||
| Fwd PE | 18.82 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 96.36% of the companies listed in the same industry.
94.55% of the companies in the same industry are more expensive than CRL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.86 | ||
| EV/EBITDA | 12.76 |
4.3 Compensation for Growth
The decent profitability rating of CRL may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.6
EPS Next 2Y-1.17%
EPS Next 3Y2.89%
5. Dividend
5.1 Amount
CRL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHARLES RIVER LABORATORIES
NYSE:CRL (11/22/2024, 8:04:00 PM)
After market: 195.77 0 (0%)195.77
+1.58 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.01B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.34 | ||
| Fwd PE | 18.82 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)1.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.16% | ||
| ROE | 10.92% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 15.04% | ||
| PM (TTM) | 10.17% | ||
| GM | 35.93% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.48 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-9.4%
EPS 3Y9.37%
EPS 5Y
EPS Q2Q%
EPS Next Y-3.64%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y12.2%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y